Conditions: Carcinoma, Non-Small-Cell Lung
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 43
Healthy volunteers: no

Brief summary:
To explore the efficacy of BIBW 2992 defined by the objective response rate (Complete Response, Partial Response) as determined by Response Evaluation Criteria in Solid Tumours\[RECIST\] 1.1 in the patients with advanced (stage IIIB or IV) adenocarcinoma of the lung harbouring wild-type EGFR.

Detailed description:

Arms:
arm 1: patient to receive afatinib(BIBW 2992) po QD in an open-label manner

Interventions: intervention 1: afatinib (BIBW 2992)
Intervention descriptions: intervention 1: afatinib (BIBW 2992) po QD

Protocol document: